Antibodies to tumour necrosis factor α as treatment for Crohn's disease
- 1 March 2000
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 355 (9207), 858-860
- https://doi.org/10.1016/s0140-6736(99)00442-0
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- The relationship between infliximab treatment and lymphoma in Crohn's diseaseGastroenterology, 1999
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trialGastroenterology, 1999
- Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications.International Journal of Colorectal Disease, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's diseaseThe Lancet, 1997
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Long-term neoplasia risk after azathioprine treatment in inflammatory bowel diseaseThe Lancet, 1994
- Lymphoma in inflammatory bowel diseaseCancer, 1992